KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) FCF Margin (2016 - 2025)

Historic FCF Margin for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to 42.84%.

  • Teva Pharmaceutical Industries' FCF Margin rose 87400.0% to 42.84% in Q4 2025 from the same period last year, while for Dec 2025 it was 12.46%, marking a year-over-year increase of 19100.0%. This contributed to the annual value of 12.46% for FY2025, which is 19100.0% up from last year.
  • Teva Pharmaceutical Industries' FCF Margin amounted to 42.84% in Q4 2025, which was up 87400.0% from 5.2% recorded in Q3 2025.
  • Teva Pharmaceutical Industries' 5-year FCF Margin high stood at 47.5% for Q4 2023, and its period low was 13.94% during Q1 2021.
  • For the 5-year period, Teva Pharmaceutical Industries' FCF Margin averaged around 8.01%, with its median value being 4.17% (2025).
  • Its FCF Margin has fluctuated over the past 5 years, first crashed by -180000bps in 2021, then skyrocketed by 261000bps in 2023.
  • Over the past 5 years, Teva Pharmaceutical Industries' FCF Margin (Quarter) stood at 7.39% in 2021, then soared by 190bps to 21.4% in 2022, then surged by 122bps to 47.5% in 2023, then decreased by -28bps to 34.1% in 2024, then grew by 26bps to 42.84% in 2025.
  • Its FCF Margin was 42.84% in Q4 2025, compared to 5.2% in Q3 2025 and 3.14% in Q2 2025.